Treating type 2 diabetes is no longer a one-size-fits-all endeavor. As new therapies emerge, clinicians face the ongoing challenge of selecting and sequencing medications in a way that balances efficacy, safety, cost, and patient preference. This comprehensive guide to type 2 diabetes drug sequencing outlines practical strategies for initiating, intensifying, …
Read More »Beyond GLP‑1s: Are We Overlooking the Role of SGLT2 Inhibitors and Metformin?
Clinicians and care teams are increasingly focused on GLP‑1 receptor agonists, but SGLT2 inhibitors and metformin in diabetes management remain foundational in achieving comprehensive, evidence‑based outcomes. While GLP‑1 therapies generate headlines for weight loss and glucose control, 2025 guidelines still strongly emphasize the cardioprotective and renoprotective benefits of SGLT2 inhibitors …
Read More »GLP‑1s Beyond Weight Loss: Are We Overlooking Neuroprotective Benefits?
The class of medications known as GLP-1 receptor agonists — commonly prescribed for type 2 diabetes and increasingly used for weight loss — may offer more than just metabolic benefits. Growing evidence indicates that GLP-1 drugs could play a role in protecting the brain. Could this mean a dual benefit …
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.